Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01124552 · ClinicalTrials.gov registry record · Phase 2

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

A Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, sponsored by Revance Therapeutics.

Completed
Registry status
Phase 2
Development phase
180
Enrollment target
1
Study location

NCT01124552: Completed Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, sponsored by Revance Therapeutics.

NCT01124552 is a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines that has completed, run by Revance Therapeutics. The registered enrollment target is 180 participants, above the 57-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (216% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01124552, a Phase 2 study of Facial Wrinkles and Lateral Canthal Lines, has completed, sponsored by Revance Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if an investigational drug, called RT001 Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet wrinkles.

Primary Outcome

The number of subjects who show improvement based on the investigator global assessment

Interventions

  • DRUG Placebo
  • OTHER Vehicle
  • DRUG RT001 Botulinum toxin type A (Dose A)
  • DRUG RT001 Botulinum Toxin Type A (Dose B)

Study Locations (1)

Florida

  • Dermatology Research Institute, LLC - Coral Gables

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2010-04
Est. Completion 2010-07
Phase Phase 2
Revance Therapeutics

27 total trials

What the finished NCT01124552 record still lists

NCT01124552 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 57-participant average among 6 other Facial Wrinkles trials with a reported enrollment target (216% higher).

The record links to 3 conditions, with Facial Wrinkles appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT01124552 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT01124552 about?

NCT01124552 is a clinical study titled "A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults". The purpose of this study is to find out if an investigational drug, called RT001 Topical Gel, is safe and useful in minimizing the wrinkles between the eye and hairline called lateral canthal lines, also known as crow's feet wrinkles.

What is the current status of trial NCT01124552?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2010-04. Estimated completion is 2010-07.

What conditions does trial NCT01124552 study?

This clinical trial studies the following conditions: Facial Wrinkles, Lateral Canthal Lines, Crows Feet.

What interventions are being tested in trial NCT01124552?

The interventions under investigation include: Placebo (DRUG), Vehicle (OTHER), RT001 Botulinum toxin type A (Dose A) (DRUG), RT001 Botulinum Toxin Type A (Dose B) (DRUG).

Who is sponsoring clinical trial NCT01124552?

This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01124552 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Facial Wrinkles

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01124552, the US trial registry maintained by the National Library of Medicine. NCT01124552 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.